Allogene Therapeutics (ALLO) Operating Leases (2019 - 2025)
Allogene Therapeutics (ALLO) has disclosed Operating Leases for 7 consecutive years, with $75.0 million as the latest value for Q4 2025.
- Quarterly Operating Leases fell 17.31% to $75.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $75.0 million through Dec 2025, down 17.31% year-over-year, with the annual reading at $75.0 million for FY2025, 17.31% down from the prior year.
- Operating Leases hit $75.0 million in Q4 2025 for Allogene Therapeutics, down from $77.1 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $98.2 million in Q2 2022 to a low of $51.2 million in Q2 2021.
- Historically, Operating Leases has averaged $82.4 million across 5 years, with a median of $88.9 million in 2024.
- Biggest five-year swings in Operating Leases: skyrocketed 54586.0% in 2021 and later decreased 17.31% in 2025.
- Year by year, Operating Leases stood at $69.9 million in 2021, then surged by 36.03% to $95.1 million in 2022, then dropped by 7.12% to $88.3 million in 2023, then grew by 2.73% to $90.8 million in 2024, then fell by 17.31% to $75.0 million in 2025.
- Business Quant data shows Operating Leases for ALLO at $75.0 million in Q4 2025, $77.1 million in Q3 2025, and $87.0 million in Q2 2025.